2Murray C J, Lopez AD, Black R, et al. Global Burden of Disease 2005: call for collaborators. Lancet,2007, 370(9582) :109-110.
3Tatjana Savic-Stankovic, Milica Jovanovic-Medojevic, Slavoljuh Zivkovic. Dental Status of Institutionalized Persons with Special Needs who Live in Special Institution" Srce u jabuci" in Pancevo. Serbian Dental Journal ,2011,58 : 16-22.
5Kisely S, Quek LH, Pais J, et al. Advanced dental disease in peo- ple with severe mental illness : systematic review and meta-analysis. Br J Psychiatry, 2011,199(3) :187-193.
7Amaiz A, Zumdrraga M, Diez-Altuna I, et al. Oral health and the symptoms of schizophrenia. Psychiatry Res, 2011,188 (1) :24-28.
8Purandare N, Woods E, Butler S, Morris J, et al. Dental health of community-living older people attending secondary healthcare: a cross-sectional comparison between those with and without diag- nosed mental illness. Int Psychogeriatr, 2010,22 (3) :417-425.
9A1-Mobeeriek A. Oral health status among psychiatric patients inRiyadh, Saudi Arabia. West Indian Med J, 2012 , 61 ( 5 ) : 549- 554.
10Ponizovsky AM, Zusman SP, Dekel D, et al. Effect of implemen- ting dental services in Israeli psychiatric hospitals on the oral and dental health of inpatients. Psychiatr Serv, 2009,60 (6) :799-803.
4Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizo- phrenia patients: a double-blind, placebo-controlled study [ J]. Am J Psychiatry, 2008,165 (3) :352-358.
5Behdani F, Hebrani P, Rezaei Ardani A, et al. Effect of topira- mate augmentation in chronic schizophrenia: a placebo-controlled trial[J]. Arch Iran Med, 2011,14(4) :270-275.
6Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topira- mate on olanzapine-related adiposity in women: a random, double- blind, placebo-controlled study [ J ]. J Clin Psychopharmacol, 2005,25 (3) :211-217.
7Narula PK, Rehan HS, Unni KE, et al. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial [ J ]. Schizoohr Res. 2010.118 ( 1-3 ) :218-223.
8Alvarez-Jimnez M, Gonz61ez-Blanch C, Crespo-Facorro B, et al. Antipsychotic-induced weight gain in chronic and first-episode psy- chotic disorders: a systematic critical reappraisal[ J]. CNS Drugs, 2008,22 (7) :547-562.
9Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review [ J ]. CNS Drugs, 2005,19 Suppl 1 : 1-93.
10Ko YH, Joe SH, Jung IK, et al. Topiramate as an adjuvant treat- ment with atypical antipsychotics in schizophrenic patients experi- encing weight gain [ J ]. Clin Neuropharmacol, 2005,28 ( 4 ) : 169-175.
